LEADER 05188nam 22006494a 450 001 9910144557003321 005 20210901104915.0 010 $a1-280-85409-X 010 $a9786610854097 010 $a3-527-60753-6 010 $a3-527-60700-5 035 $a(CKB)1000000000377170 035 $a(EBL)482272 035 $a(OCoLC)70054438 035 $a(SSID)ssj0000140421 035 $a(PQKBManifestationID)11132252 035 $a(PQKBTitleCode)TC0000140421 035 $a(PQKBWorkID)10053445 035 $a(PQKB)11112891 035 $a(MiAaPQ)EBC482272 035 $a(EXLCZ)991000000000377170 100 $a20060628d2005 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aDNA pharmaceuticals$b[electronic resource] $eformulation and delivery in gene therapy, DNA vaccination and immunotherapy /$fedited by Martin Schleef 210 $aWeinheim $cWiley-VCH$dc2005 215 $a1 online resource (277 p.) 300 $aDescription based upon print version of record. 311 $a3-527-31187-4 320 $aIncludes bibliographical references and index. 327 $aDNA Pharmaceuticals; Preface; Contents; List of Contributors; Abbreviations; 1 DNA Vaccines - An Overview; 1.1 Rationale for DNA Vaccines; 1.2 Preclinical Proof of Concept; 1.3 Clinical Trials; 1.4 Second-Generation Vaccines; 1.5 Conclusions; References; 2 DNA as a Pharmaceutical - Regulatory Aspects; 2.1 Introduction; 2.2 Quality Requirements for DNA used as a Gene Therapy Product; 2.2.1 Introduction; 2.2.2 Production and Purification; 2.2.2.1 Raw Materials; 2.2.2.2 Antibiotics; 2.2.2.3 Solvents; 2.2.2.4 Fermentation; 2.2.2.5 Purification; 2.2.3 Cell Banking System Procedures 327 $a2.2.3.1 Generation and Characterization of Master and Working Cell Banks2.2.4 Product Characterization and Quality Criteria; 2.2.4.1 Identity; 2.2.4.2 Purity; 2.2.4.3 Adventitious Agents; 2.2.4.4 Potency; 2.3 Safety Studies for Clinical Trials; 2.3.1 General Considerations; 2.3.2 Conduct of Preclinical Safety Studies; 2.3.2.1 Regulations; 2.3.2.2 Design of an Appropriate Toxicology Program; 2.3.2.3 Single- and Repeat-Dose Toxicity Studies; 2.3.2.4 Safety of the Formulated Plasmid DNA; 2.3.2.5 Specific Safety Considerations; 2.3.2.6 Choice of Animal Model; 2.4 Special Issues 327 $a2.4.1 Comparability of Plasmid Gene Therapy Products2.4.2 Mixed Plasmid Preparations; 2.4.3 Plasmid Molecular Structure; 2.5 Biosafety Issues and Environmental Risk Assessment; References; 3 From Bulk to Delivery: Plasmid Manufacturing and Storage; 3.1 Introduction; 3.1.1 Gene Therapy; 3.1.2 DNA Vaccination; 3.2 Manufacturing of Plasmid DNA; 3.2.1 Bacterial Cultivation; 3.2.2 Plasmid DNA Purification; 3.2.3 Innovative Aspects in Plasmid Manufacturing; 3.3 Quality Control of Plasmid DNA Vectors; 3.3.1 Proteins, Ribonucleic Acid, and Lipopolysaccharides; 3.3.2 Chromosomal DNA 327 $a3.3.3 Plasmid Identity3.3.4 Plasmid Topology (Structural Homogeneity); 3.4 Plasmid Stability during Storage and Application; 3.4.1 Long-Term Stability of Plasmid DNA; 3.4.2 Lyophilization for Long-Term Storage; 3.4.3 Stability during Application; 3.5 Future Developments; References; 4 Minimized, CpG-Depleted, and Methylated DNA Vectors: Towards Perfection in Nonviral Gene Therapy; 4.1 Introduction; 4.2 The Mammalian Immune System as a Barrier to Nonviral Gene Delivery; 4.3 Strategies to Minimize DNA Vectors 327 $a4.3.1 Excision of a DNA Fragment Containing a Transgene Expression Cassette from Plasmid DNA4.3.2 Intramolecular Site-Specific Recombination Within a Bacterial Plasmid; 4.3.3 Synthesis of Minimized DNA Vectors by PCR; 4.3.4 Improvement of Minimized DNA Vector Yield and Purity; 4.4 Depletion of CpG Dinucleotides in the Bacterial Vector Backbone; 4.5 Methylation of CpG Dinucleotides in Plasmid DNA; 4.6 Towards an Ideal Nonviral Vector; 4.7 Conclusion; References; 5 Localized Nucleic Acid Delivery: A Discussion of Selected Methods; 5.1 Foreword; 5.2 Nucleic Acid Delivery - What For? 327 $a5.3 Nucleic Acid Delivery - How? 330 $aWith its focus on a completely novel class of pharmaceuticals, this book collates the hitherto scarce literature about DNA drug formulation keenly desired by biotechnologists, molecular biologists and pharmacists, as well as those working in the biotechnological and pharmaceutical industries.As such, this volume presents a wide range of gene delivery systems needed for different therapeutic applications. It fills the gap between research and clinical trials and describes pharmaceutical fundamentals for the development of efficient DNA pharmaceuticals. 606 $aDNA vaccines 606 $aGene therapy 606 $aImmunotherapy 608 $aElectronic books. 615 0$aDNA vaccines. 615 0$aGene therapy. 615 0$aImmunotherapy. 676 $a615.372 676 $a616.0796 701 $aSchleef$b M$g(Martin)$0872773 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910144557003321 996 $aDNA pharmaceuticals$92197281 997 $aUNINA